Long-term follow-up for people treated with REACT
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study checks long-term health outcomes in people who previously received a treatment called REACT for chronic kidney disease. It may help doctors understand how safe and effective REACT is over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have previously received REACT for chronic kidney disease in an earlier study (RMCL-002, REGEN-003, or REGEN-004).
- You must have completed the end-of-study visit in that earlier (parent) study as planned.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who previously received an experimental treatment called REACT for chronic kidney disease in earlier clinical trials. Its goal is to monitor their health over time.
This study follows adults with chronic kidney disease who are not on dialysis. It aims to better understand kidney health and test what care or monitoring might help over time.
This study is looking at how immune cells called T-cells work in people with long-term kidney failure. It tests whether these cells can be changed in the lab to help treat the condition.
This is a follow-up study for people who already participated in the STEPS research project about improving fairness in organ transplants. Researchers want to track how participants are doing over time and learn more about transplant outcomes.
This early study (Phase 1) tests whether an intravenously given, donated stem cell product is safe for people with chronic kidney disease. It mainly looks at side effects and whether the treatment can be given without harming you.
This study follows people who are getting a kidney transplant (first or later) to better understand how the body recovers, using health tracking and “gene/protein” (proteogenomic) information. It may help doctors predict complications and improve care after transplant.
Hear when a new Diabetic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.